29 results about "Keratinocyte" patented technology

The present invention relates to a method for producing a skin tissue model, comprising: (a) isolating and culturing fibroblasts and keratinocytes from skin tissue; (b) preparing a bioink composition for a dermal layer and a bioink composition for an epidermal layer, the bioink composition containing the isolated cells; and (c) producing a skin tissue model using the bioink composition for a dermal layer and the bioink composition for an epidermal layer.

This invention discloses a method for culturing skin organoids for large-scale production and the skin organoids used for large-scale production, belonging to the fields of tissue engineering and biomanufacturing technology. The method involves laying a dermal matrix layer composed of orthogonal double-network hydrogels embedding fibroblasts in a bioreactor containing multiple independently operable culture modules. After inoculating keratinocytes, negative pressure is used to drive a uniform descent of the culture medium level to achieve gas-liquid interface culture. The first network of the orthogonal double-network hydrogel is formed by photocrosslinking of methacrylamide recombinant collagen, and the second network is formed by Michael addition of thiolated polysaccharides and multi-arm polyethylene glycol maleimide. During the culture process, the barrier maturity is assessed in real time by online monitoring of transepithelial resistance, and the negative pressure is controlled accordingly. A single batch can produce 3000 cm³ of skin organoids. 2 The above-mentioned qualified skin organoids have a transepithelial resistance coefficient of variation of less than 10%.

This invention discloses a method for inducing pluripotent stem cells to differentiate into skin keratinocytes and its culture medium, solving problems such as long differentiation cycles, low yields, insufficient purity, and animal-derived contamination in existing technologies. The first stage uses medium I containing FGF2 and tanshinone IIA to promote mesodermal differentiation. The second stage uses medium II containing BMP4, EGF, dexamethasone, and PVA to regulate and synergistically induce the BMP / ERK signaling pathway. The final stage uses medium III for expansion culture, obtaining fibroblasts with a purity >99% within 20 days. This method is non-invasive, simple, and low-cost, with potential for large-scale production. The obtained cells can be used for skin regeneration, disease modeling, drug screening, and clinical treatment, demonstrating significant medical application and industrial transformation value.

This invention relates to the field of probiotic screening and application technology, specifically to a Bifidobacterium adolescentis HC2916 that inhibits melanin synthesis, its microbial preparations, and applications. Bifidobacterium adolescentis HC2916 was deposited on May 16, 2023, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 27352. This strain exhibits excellent antioxidant capacity, capable of scavenging various free radicals and inhibiting lipid peroxidation. Furthermore, its fermentation supernatant and lysate significantly downregulate the protein and mRNA expression of MITF, a core factor in melanin production signaling, and inhibit the expression of its downstream key enzymes TYRP1 and TYRP2. This effectively suppresses UVA-induced increases in melanin content in skin keratinocytes, demonstrating promising application prospects in the field of skin whitening.

The application relates to the technical field of skin care products, and particularly discloses a transdermal absorption whitening supermolecular composition and application thereof. The composition comprises a solvent, an external water-phase stabilizer dissolved in the solvent and whitening supermolecular particles dispersed in the solvent; the whitening supermolecular particles comprise an outer elastic liposome, the outer elastic liposome is wrapped with a water-soluble whitening agent, a water-soluble anti-glycation agent and small liposome particles; the outer elastic liposome is loaded with a penetration enhancer, a barrier repair agent and a cell autophagy activator, and the outer surface of the outer elastic liposome is also adsorbed with a keratinocyte target positioning agent; the small liposome particles comprise an inner elastic liposome, the inner elastic liposome is wrapped with a cyclodextrin-peptide amido supermolecular inclusion compound; the inner elastic liposome is loaded with an oil-soluble anti-glycation agent, and the inner elastic liposome is inlaid with a melanocyte target positioning agent. The application has the advantage of further improving the whitening effect.

The present application relates to the use of a substance that regulates BCL11A gene and / or its encoded product in the preparation of a drug for reversing skin photoaging, wherein the skin photoaging includes skin cell aging caused by sunlight, light, etc., and the skin cells include keratinocytes, dermal fibroblasts, melanocytes. The regulation is to up-regulate the expression of BCL11A gene and / or promote the production of its encoded product. Typical clinical manifestations of the skin photoaging include wrinkles, dry skin, loose skin, dilated capillaries, uneven skin pigmentation, and skin itching. The substance that regulates BCL11A gene and / or its encoded product includes a substance that regulates BCL11A gene DNA molecules and a substance that regulates the expression of BCL11A translation product protein molecules. The reversal of skin photoaging is manifested in reducing the proportion of cells positive for aging-related beta-galactosidase staining in skin cells and reducing the expression of aging-related protein p16 and DNA damage protein gammaH2AX.

The application provides a composition for regulating intestinal flora to intervene in rose acne, comprising oral preparations and skin external preparations thereof, and relates to the technical field of biological medicines.The composition is composed of a prebiotic component inulin or a dandelion water extract containing inulin, and a humanized rhamnosus strain or a bacterial body lysate, culture supernatant or metabolite thereof.The composition can promote the proliferation of the humanized rhamnosus in the intestinal tract after being taken orally, significantly enhance the tryptophan metabolism capacity of the humanized rhamnosus, and improve the intestinal indole-3-lactic acid level;ILA enters blood through the intestinal-skin axis, and acts on the skin keratinocyte aromatic receptor, so that the immune homeostasis is systematically regulated and the skin inflammation is relieved.Experiments prove that the composition has a significant prevention and intervention effect on a rose acne model of mice induced by LL-37, can reduce the erythema area, and relieve the inflammatory symptoms.

This invention discloses lotus-derived LEA protein and its application in improving skin's resistance to dryness damage, belonging to the field of biotechnology and its application in skin care technology. The amino acid sequence of the LEA protein is shown in SEQ ID NO:1. This invention successfully constructed a recombinant expression vector containing a nucleic acid molecule encoding the LEA protein using genetic engineering methods, and transformed it into *E. coli* for efficient expression. After purification, the target protein was obtained. This LEA protein can significantly protect human immortalized keratinocytes against dryness damage. At a concentration of 100-200 μg / mL, it can restore cell viability under dryness stress to over 85%, with effects comparable to hyaluronic acid. This LEA protein has good biocompatibility and significant anti-dryness activity, and can be used to prepare skin care products that protect skin cells against dryness damage, moisturize, repair the skin barrier, or have anti-aging effects, showing broad application prospects.

The application discloses arginase 2 inhibiting peptides and application thereof in wound healing. The arginase 2 inhibiting peptide has an amino acid sequence as shown in SEQ ID No. 1 or a mutant sequence thereof. It is found through research of the application at a cell level and in a mouse skin wound model that MUT4-short peptide and MUT5-short peptide can effectively improve the viability and migration ability of keratinocytes under high-sugar conditions in vitro and in a metabolic abnormality model in vivo, reduce the intracellular reactive oxygen level, and promote the repair process of skin wounds, wherein the MUT4-short peptide shows more significant in promoting the recovery of cell functions and accelerating wound healing, and has a good application prospect in promoting skin wound healing, especially in the treatment of difficult-to-heal wounds related to metabolic diseases such as diabetes.

The present application provides a compound capable of simultaneously inhibiting heparanase and MMP activity, which is a compound shown in the following general formula: wherein A1 is a carbon atom or a nitrogen atom, A2 is a carbon atom; the bond A1-A2 is a single bond, a double bond, or is connected with a benzene ring or a cyclohexene ring; the five-membered ring can also be replaced by a six-membered ring. The compound has the functions of maintaining the integrity of epidermal structure, promoting the differentiation of keratinocytes, and regulating the function of skin barrier.

The application discloses a kind of recombinant humanized collagen composition for removing freckle and preparation method and application thereof, and composition includes recombinant humanized collagen and histidine;The recombinant humanized collagen includes unit A and unit B, the unit A is the amino acid sequence of the 168~554 fragment of human source III collagen chain alpha-1 chain;The unit B is the amino acid sequence of the 1127~1163 fragment of human source III collagen chain alpha-1 chain, the unit A and the unit B are connected using linker.The recombinant humanized collagen has the effect of promoting keratinocyte proliferation and inhibiting tyrosinase;Further, the recombinant humanized collagen is compounded into composition with histidine, sponge bone needle and allantoin, the composition has good whitening and freckle-removing effect and low skin irritation, and users are widely applicable.

The application discloses application of keratin 14 or a glycosylation modifier thereof in preparation of a product for treating systemic lupus erythematosus. The keratin 14, as a component of skin keratinocytes, has small toxic and side effects. The first research of the application shows that the keratin 14 has certain potential in treating systemic lupus erythematosus, and use of the keratin 14, a body self component, can greatly shorten research and development cost and research and development risk. The application first explores the effect of the keratin 14 in treating systemic lupus erythematosus, and provides an experimental basis for treatment of systemic lupus erythematosus.

By applying a structural analysis approach to stratum corneum samples taken from humans, the barrier function of the skin at any given location can be measured, and the type of skin barrier function, which differs depending on the ambient temperature and humidity, can be determined. [Solution] Based on the results of structural analysis of intercellular lipids or keratinocyte properties of stratum corneum collected from the skin of multiple individuals, and the corresponding values ​​of barrier properties based on the permeability of indicator substances in living skin kept in a low humidity environment, an axis of high and low barrier properties of the stratum corneum in a low humidity environment is obtained. Similarly, an axis of high and low barrier properties of the stratum corneum in a high humidity environment is obtained when it is kept in a high humidity environment. Then, structural analysis is performed on the stratum corneum collected from the skin of a subject when it is kept in the low humidity environment, and structural analysis is performed when it is kept in the high humidity environment. The barrier properties of the subject's skin are then classified according to the axes of high and low barrier properties of the stratum corneum in a low humidity environment and the axes of high and low barrier properties of the stratum corneum in a high humidity environment.

This invention discloses a deer antler mushroom extract, its preparation method, and its application in promoting skin barrier repair, belonging to the field of biotechnology. The preparation method includes: extracting the fruiting bodies of deer antler mushrooms using ethanol solution as the extraction solvent and employing a progressively decreasing material-to-liquid ratio; combining the extracts to obtain a deer antler mushroom ethanol extract; extracting the residue of the deer antler mushroom ethanol extract using water as the extraction solvent and employing a progressively decreasing material-to-liquid ratio, and combining the extracts; subjecting the extracts to alcohol precipitation to obtain a deer antler mushroom water-extracted polysaccharide; and combining the deer antler mushroom ethanol extract and the deer antler mushroom water-extracted polysaccharide to obtain the deer antler mushroom extract. The deer antler mushroom extract prepared by this invention has a dual function: inhibiting hyaluronidase activity and repairing the skin barrier by promoting keratinocyte proliferation and migration and upregulating the expression of barrier-related genes. It has clear and broad application prospects in the fields of cosmetics and skin repair pharmaceuticals.

This invention relates to the fields of biomedical engineering and regenerative medicine, and particularly to a plasma matrix composite membrane activated by autologous keratinized epithelial tissue fragments, its preparation method, and its applications. The composite membrane is obtained by mixing autologous keratinized epithelial tissue fragments with a liquid autologous plasma matrix in a specific ratio, utilizing tissue factors on the surface of the tissue fragments to trigger platelet activation, spontaneously forming a gel, and then pressing it into a membrane. This invention is the first to utilize the biointerface of autologous keratinized epithelial tissue fragments to activate platelets, eliminating the need for exogenous thrombin and achieving completely autologous in-situ gelation. The composite membrane formed after pressing possesses excellent mechanical properties and barrier function, and can be prepared in a single operation in the operating room without the need for in vitro cell culture. The composite membrane of this invention is used for oral soft tissue augmentation, such as widening of keratinized gingiva and alveolar ridge soft tissue augmentation, and has advantages such as no donor site damage, high biosafety, and ease of operation.

This invention belongs to the field of cosmetic technology, specifically relating to a composition with water-locking and brightening functions and its targeted microcarrier delivery system. The water-locking and brightening composition provided by this invention mainly consists of niacinamide, tranexamic acid, oat β-glucan, disodium EDTA, and sodium hyaluronate. This composition can achieve a synergistic effect of water locking and brightening, effectively improving dullness, dryness, and uneven skin tone. Simultaneously, this invention also provides a targeted microcarrier delivery system, which is prepared by encapsulating the above composition in an internal aqueous phase using liposome technology, and simultaneously covalently attaching a targeting ligand to the surface of the liposomes. The targeted microcarrier delivery system obtained by this invention can actively target melanocytes and keratinocytes, achieving precise delivery of brightening and water-locking ingredients, significantly improving skin tone and addressing the root causes of dullness and uneven skin tone.

The present application belongs to the field of cell and tissue culture, and particularly relates to a culture medium for promoting proliferation of primary human epidermal melanocytes, a preparation method and application thereof. The present application innovatively uses epidermal concentrate factor to promote proliferation of melanocytes. The epidermal concentrate factor is obtained by collecting and concentrating the culture medium of keratinocytes. By simulating the in-vivo microenvironment, the epidermal concentrate factor prepared by the present application can effectively activate the proliferation signal pathway of melanocytes. The concentrate factor contains various growth factors and cytokines secreted by keratinocytes, which can synergistically enhance the division ability of melanocytes. Compared with the traditional culture method, after adding the epidermal concentrate factor, the population doubling time of primary melanocytes is significantly shortened, and the stable pigment production function is maintained.

Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.

The application discloses application of leptin in preparation of a medicine for promoting hair growth, and belongs to the technical field of biological medicines. The leptin provided in the application is expressed in hair matrix cells of a growing hair follicle, activates a JAK-STAT signal path, and induces continuous proliferation of hair matrix cells, so as to promote the hair follicle to enter the growing period in advance, prolong the time length of the growing period of the hair follicle, promote differentiation of the hair matrix cells into keratinocytes, maintain continuous growth of the hair shaft, and further prolong the length of the hair shaft.

The application belongs to the technical field of cosmetics, and discloses a portulaca oleracea seed oil, a preparation method and application thereof, cosmetics, medicines and food. The portulaca oleracea seed oil comprises, in percentage by mass, 33-37% of linoleic acid, 24-27% of linolenic acid, 15-18% of oleic acid, 14-16% of palmitic acid, 3.5-4.5% of stearic acid, 0.5-1% of isooleic acid and 0.3-0.4% of behenic acid. The portulaca oleracea seed oil prepared by the preparation method of the application can effectively promote the proliferation of immortalized keratinocytes, reduce the production of inflammatory factors, has strong anti-inflammatory effect, can promote the expression of filaggrin and tight junction protein genes and has barrier repair effect. The preparation method of the portulaca oleracea seed oil comprises sequentially drying, seed oil extraction, seed oil purification, decolorization, impurity removal and drying to obtain the portulaca oleracea seed oil, and has the advantages of simple operation, high yield, low cost, stable product quality, green and environment-friendly process and suitability for large-scale production.

The application discloses a pearl capsule antibacterial peptide and application thereof, and belongs to the technical field of biological medicine. The amino acid sequence of the pearl capsule antibacterial peptide is KRLF. The theoretical molecular weight is 562.76 Da, the isoelectric point is 11.54, the net charge is +2 at pH=7.0, and the antibacterial experiment result shows that the polypeptide has broad-spectrum and high-efficiency antibacterial activity and has obvious inhibiting effect on the proliferation of gram-positive bacteria and gram-negative bacteria. The safety evaluation experiment result shows that the antibacterial peptide is beneficial to the proliferation of keratinocytes and fibroblasts and is safe and non-toxic.

The present invention aims to provide a method for producing iPS cell-derived keratinocytes that can induce keratinocytes that highly express keratinocyte markers in a feeder-free and serum-free environment. [Solution] A method for producing iPS cell-derived keratinocytes, comprising an induction step of inducing iPS cells into keratinocytes using one or more induction media in a feeder-free and serum-free environment, wherein for at least a portion of the induction step, a medium containing fibroblast growth factor 7 (FGF7) is used as the induction medium.

This invention discloses a 3D cell sphere for treating skin defects, its preparation method, and its applications, belonging to the field of biomedical materials. The 3D cell sphere is formed by the self-assembly of keratinocytes (KCs) and cells capable of secreting extracellular matrix, possessing a biomimetic hierarchical structure similar to natural skin, filled with extracellular matrix, and the KCs can form functional epidermal-associated structures. The preparation method involves obtaining EKCs through directed induction differentiation of pluripotent stem cells, which are then spontaneously assembled with cells capable of secreting extracellular matrix to form 3D cell spheres. The 3D cell sphere exhibits excellent biocompatibility, a simple preparation process, and can be mass-produced, with convenient operation. It is suitable for repairing various acute and chronic skin defects such as large-area thermal burns, diabetic foot ulcers, and pressure ulcers, effectively accelerating wound healing and improving the quality of epidermal regeneration. It addresses the pain points of traditional treatments, such as scarcity of skin cells, complex procedures, and poor efficacy, providing a safe and efficient novel cell therapy for skin defect repair.

This invention discloses a method for extracting lipid components from dermal adipocytes and its application, comprising the following steps: (1) extracting primary dermal fibroblasts from mice on day 0 of birth; (2) culturing the primary dermal fibroblasts in DMEM+++ medium until the cell adhesion density reaches 100%, then inducing adipogenic differentiation in vitro using adipogenic differentiation medium, and then maintaining the culture in maintenance medium until the cells are in an early adipogenic state, and separating the supernatant of the early differentiated cells; (3) extracting and separating the supernatant obtained in step (2) using the Matyash method to obtain the lipid components of the dermal adipocytes. This invention, by extracting and separating lipid and protein components from the supernatant of early differentiated adipocyte culture, obtains lipid components with significant immunomodulatory functions, which can significantly inhibit the inflammatory state of macrophages and the proliferation of keratinocytes.

The present disclosure relates to a composition for preventing, alleviating, or treating cancer, the composition including a skin keratinocyte-derived extracellular matrix (ECM) as an active ingredient. The composition for preventing, alleviating, or treating cancer of the present disclosure includes the keratinocyte-derived ECM as an active ingredient, thereby significantly reducing only proliferation of cancer cells without causing side effects such as cytotoxicity in normal cells such as fibroblasts constituting the dermis of normal skin. In addition, the composition for preventing, alleviating, or treating cancer of the present disclosure was observed to: expect a significant effect in targeted therapy as well as MCF7 among breast cancer cell; have an effect of suppressing the proliferation of MDA-MB-231; be able to significantly suppress proliferation of Caki-1 and Caki-2,; and significantly reduce proliferation of PANC-1.

This invention discloses an active polypeptide NP-VV-3 that promotes oral ulcer healing and its applications, belonging to the field of biomedical technology. The amino acid sequence of the active polypeptide NP-VV-3 is: VVPAFVLLKKAIRIMFKRNC. In in vitro experiments, polypeptide NP-VV-3 significantly promoted scratch closure of human immortalized keratinocytes at concentrations as low as 1 nM, demonstrating a dose-dependent healing-promoting ability. Transwell migration assays further confirmed that polypeptide NP-VV-3 significantly enhanced the migration ability of HaCaT cells at concentrations of 1 nM and 10 nM, indicating that it can accelerate wound repair by promoting epithelial cell migration. The polypeptide NP-VV-3 provided by this invention provides an important candidate molecule for the development of novel, highly effective, and low-irritation drugs for the treatment of oral ulcers.

The application discloses a hydroxybutyl chitosan-based composite plant anti-inflammatory composite material and a preparation method thereof. Relying on the unique temperature-sensitive phase change characteristics of HBCS, the phase change mechanism is triggered when contacting the skin, and sustained slow-release power is provided for anti-inflammatory repair components, so that the action time of the effective components is greatly prolonged. The application not only utilizes the direct anti-inflammatory signal inhibition effect of EGCG and spilanthes acmella, but also innovatively exerts the immunoregulatory activity of HBCS itself; HBCS can preliminarily modulate the receptor activity of macrophages and keratinocytes, and forms a complementary enhancement effect of 'pre-modulation and post-inhibition' with subsequent effective components, and finally realizes the strong anti-inflammatory and repair effect far beyond single component. The system realizes the synergistic anti-inflammatory effect of the carrier and the functional components through the removal of 'bad cells' by gynostemma pentaphyllum, the modification of 'good cells' by HBCS, the blockage of 'inflammatory signals' by EGCG combined with gynostemma pentaphyllum, and the maintenance of'system balance' by spilanthes acmella cooperated with gynostemma pentaphyllum.

The application discloses application of VEGF-B in psoriasis. The application research shows that up-regulation of VEGF-B expression in a psoriasis animal model can significantly reduce the levels of inflammatory factors such as IL-1beta and TNF-alpha, and reduce dermal immune cell infiltration; meanwhile, the up-regulation of VEGF-B expression can inhibit excessive proliferation of keratinocytes, promote normal differentiation of the epidermis, and thus reverse the formation of scales and skin thickening. Unlike existing anti-VEGF-A strategies, the application proves that enhancement of VEGF-B signals can be anti-inflammatory and restorative, and provides a new treatment target for psoriasis. The application breaks through the limitations of traditional anti-VEGF-A therapy, and expands the clinical value of VEGF family members.

The application discloses a lactic acid bacteria CCFM1460 which can produce multiple bioactive substances to promote skin barrier repair and a postbiotic of the lactic acid bacteria CCFM1460, and belongs to the technical field of microorganisms and medical technology.The lactic acid bacteria CCFM1460 provided in the application can produce 3,4-dihydroxyphenyl glycol, N-tetradecyl diethanolamine and 3-phenyl lactic acid through fermentation.The postbiotic of the lactic acid bacteria CCFM1460 has a good skin barrier repair effect.The cell lysate and fermentation supernatant of the lactic acid bacteria CCFM1460 can improve the cell activity of damaged keratinocytes and the expression levels of FLG, IVL and LOR genes, and the cell lysate of the CCFM1460 can improve the expression levels of ZO-1, OCCLUDIN and CLDN genes.Therefore, the lactic acid bacteria has a great application prospect in the preparation of external use or oral medicine or cosmetics for repairing skin barrier.